Haemonetics (NYSE:HAE) Releases FY 2026 Earnings Guidance

Haemonetics (NYSE:HAE) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.900-5.000 for the period, compared to the consensus earnings per share estimate of 4.920. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.3 billion.

Haemonetics Stock Up 1.8%

Shares of NYSE:HAE opened at $66.02 on Thursday. The firm’s 50-day moving average is $77.59 and its two-hundred day moving average is $65.27. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The firm has a market capitalization of $3.09 billion, a PE ratio of 19.30, a price-to-earnings-growth ratio of 1.35 and a beta of 0.28.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts predict that Haemonetics will post 4.55 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on HAE. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Barrington Research reiterated an “outperform” rating and set a $93.00 target price on shares of Haemonetics in a report on Monday. Mizuho upped their price target on Haemonetics from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. BTIG Research restated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. upped their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $84.40.

Institutional Trading of Haemonetics

A number of hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its position in shares of Haemonetics by 372.8% during the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after purchasing an additional 1,678,630 shares during the period. Millennium Management LLC raised its stake in shares of Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after buying an additional 755,592 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Haemonetics during the 3rd quarter worth about $15,703,000. Qube Research & Technologies Ltd acquired a new position in Haemonetics in the third quarter worth about $13,178,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Haemonetics in the 3rd quarter valued at $6,145,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.